Table 2.
The effect of TZDs on CV risk. The table shows a comparison between rosiglitazone and pioglitazone on lipid profile and HbA1c levels in various studies [19–23].
| TZDs versus placebo | Pioglitazone | Rosiglitazone |
|---|---|---|
| Total cholesterol | Neutral | Raised |
| LDL | Neutral | Raised |
| HDL | Raised | Raised |
| Triglycerides | Reduced | Neutral |
| HbA1c | ↓ 1–1.5% | ↓ 1–1.5% |